Structure Therapeutics Inc. carries a market capitalization of 2.47B, placing it among publicly traded companies globally. Its enterprise value stands at 1.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.47B |
| Enterprise Value | 1.67B |
Structure Therapeutics Inc. currently has 213.21M shares outstanding.
| Shares Outstanding | 213.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -5.72 |
| P/TBV Ratio | 2.16 |
| P/FCF Ratio | -20.80 |
| P/OCF Ratio | -20.20 |
Structure Therapeutics Inc. maintains a current ratio of 26.16, meaning it holds 26.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 26.16 |
| Quick Ratio | 25.59 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -14.35 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Over the trailing twelve months, Structure Therapeutics Inc. has paid 607,000.00 in income taxes, reflecting an effective tax rate of 0.51.
| Income Tax | 607,000.00 |
| Effective Tax Rate | 0.51 |
Structure Therapeutics Inc.'s stock has gained approximately 108.70199% over the past 52 weeks. The 50-day moving average sits at 43.50, while the 200-day moving average is 47.72.
| Beta (5Y) | N/A |
| 52-Week Price Change | 108.70199% |
| 50-Day Moving Average | 43.50 |
| 200-Day Moving Average | 47.72 |
| Average Volume (20 Days) | N/A |
EBITDA reached -218.24M, while operating income came in at -219.88M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -219.88M |
| Pretax Income | -169.73M |
| Net Income | -170.34M |
| EBITDA | -218.24M |
| EBIT | -219.88M |
| Earnings Per Share (EPS) | -2.63 |
Structure Therapeutics Inc. holds 1.46B in cash and equivalents against 5.79M in total debt, resulting in a net debt position of -316.17M. Total book value stands at -546.25M, with working capital of 1.43B providing operational flexibility.
| Cash & Cash Equivalents | 1.46B |
| Total Debt | 5.79M |
| Net Debt | -316.17M |
| Equity (Book Value) | -546.25M |
| Book Value Per Share | -8.43 |
| Working Capital | 1.43B |
Structure Therapeutics Inc. produced -154.74M in operating cash flow over the past twelve months. After subtracting -4.48M in capital expenditures, free cash flow totaled -159.22M - equivalent to -2.46 per share.
| Operating Cash Flow | -154.74M |
| Capital Expenditures | -4.48M |
| Free Cash Flow | -159.22M |
| FCF Per Share | -2.46 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -24.32 |
| FCF Yield | -4.81 |
Structure Therapeutics Inc. posts an Altman Z-Score of 30.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 30.88 |